What OEMs Need to Know About Medical-Grade Material Sourcing With Tariffs

The medtech tariff conversation rarely reaches the medical-grade materials that make manufacturing possible in the first place. The resin that gets molded into catheter components. The stainless steel that becomes a surgical needle. The silicone that forms the tubing, seals, and flexible bodies of devices across nearly every clinical category. These inputs don’t appear in the headline tariff numbers, but they absorb tariff exposure every day, and that exposure flows directly into device costs whether the final assembly happens offshore or right here in the United States.

The Tariff Exposure Nobody’s Mapping

When OEMs evaluate tariff risk, the analysis almost always starts and ends at the contract manufacturing relationship. They ask whether the CM is domestic, whether the finished product crosses a tariffed border, and whether the country-of-origin on the label creates duty exposure.

These are legitimate questions, and the work of understanding what it means to operate in a high-tariff trade environment is valuable. But it addresses the surface of the problem, not the root. The root is in the raw material sourcing decisions that feed every manufacturing relationship, and that layer of the cost structure has received almost no attention.

A device assembled domestically by a U.S.-based medical device contract manufacturing partner can still carry significant tariff-driven input cost inflation if that partner’s resin, stainless, or silicone suppliers are drawing from tariff-affected sources. The cost arrives in a quarterly price adjustment, a raw material surcharge buried in a line-item update, or gradual margin compression that accumulates across a product line.

Understanding the medical device supply chain at the raw material level is the only way to get ahead of that dynamic rather than simply absorbing it.

Three Materials, Three Exposure Stories

The raw materials used in medical devices span a wide range of categories, but three inputs account for a disproportionate share of the material cost base across the device market and carry distinct, documented tariff exposure profiles. These are medical-grade stainless steel, resin, and silicone.

Medical-Grade Stainless Steel

Medical-grade stainless steel is foundational to surgical instruments, needles, implants, and structural device components, and its tariff exposure operates on two fronts. The Section 232 steel tariff applies broadly regardless of country of origin. Simultaneously, China has restricted exports of molybdenum, tightening global supply and driving up input costs from a different direction entirely.

The compounding effect of duty pressure and mineral supply restriction is working through the BOM of virtually every device manufacturer that uses metal components, regardless of where final assembly occurs.

Medical-Grade Resin and Specialty Polymers

Medical-grade resin may carry the most severe and least visible tariff exposure of any input category. Petroleum-derived resins are heavily sourced from Asia. Under the current tariff environment, certain advanced thermoplastics used in medical device contract manufacturing face effective Section 301 duty rates as high as 50 percent for Chinese-origin materials.

For raw material sourcing in the resin category, this means domestic molders are paying more for feedstock, and that increase flows forward into every quoted unit price.

Medical-Grade Silicone

Medical-grade silicone presents a different but equally significant profile. The polymers, additives, and curing agents required to produce medical-specification silicone are concentrated among a small number of global suppliers drawing heavily from Asian source materials.

North America consumes medical-grade silicone at a high rate but produces relatively little of the upstream polymer inputs domestically, meaning even domestically compounded silicone often carries imported content subject to current tariff structures.

Why Substitution Isn’t a Simple Fix

In many industries, the response to raw material cost pressure is substitution. In medical device contract manufacturing, that response is constrained at nearly every turn. A resin change that takes weeks to qualify in consumer electronics can take six to eighteen months in a medical device context, requiring biocompatibility testing, design history file updates, and in many cases, regulatory submissions before the new material can be used in a cleared device.

The product lifecycle management implications of a material change are substantial, and the cost of qualification often exceeds the savings the substitution was meant to generate.

This is the structural trap that makes raw material tariff exposure particularly damaging in medtech. OEMs are caught between rising input costs and a qualification system that makes switching slow, expensive, and risky. The result is that cost increases at the medical-grade materials level tend to be absorbed rather than solved. These costs accumulate invisibly because the information needed to attribute them correctly was never part of the sourcing conversation.

Remington Medical’s contract manufacturing services are built around integrated, domestically anchored production that reduces upstream material exposure from the start.

Our Contract Manufacturing Services

What This Means for How You Evaluate Your Manufacturing Relationship

The questions that actually surface raw material sourcing exposure go deeper than the CM’s location and production costs. For OEMs who want a clear picture of their true medical-grade materials cost exposure, these are the questions worth pressing for answers on:

Where do your key inputs originate? For resin, stainless, and silicone specifically—what is the country of origin for the grades currently running, and how much of that sourcing flows through tariff-affected geographies?
How are raw material cost increases communicated? Does the CM flag input cost changes transparently, or do they surface as unexplained price adjustments at contract renewal?
What is the qualification status of alternative-source substitutes? For critical raw materials used in medical devices, has preliminary qualification work already been done, or would a sourcing shift require starting from zero?
How concentrated is the supply base? Single-source dependencies at the input level compound tariff exposure. A tariff hitting the only qualified supplier for a given grade creates immediate cost pressure with no alternative path available.

For those working through how to choose a medical device contract manufacturer, raw material sourcing is one of the criteria that matters most right now.

The Raw Material Question Is a Manufacturing Partner Question

The manufacturers navigating the current environment most effectively are the ones whose CM relationships include transparency at the input material level, not just at the production floor. Device categories that depend heavily on medical-grade stainless steel, medical-grade resin, or medical-grade silicone have ongoing, material exposure to a high tariff environment.

Scaling medical device manufacturing operations with a clear picture of that exposure in the cost model is a fundamentally different exercise than scaling with a unit price assumption that doesn’t account for what’s sitting upstream of it. The OEMs who close that gap now will be better positioned than the ones who close it after the next round of cost increases arrives without warning.

Get Clarity on Your Raw Material Exposure

If your current manufacturing cost model doesn’t account for where your medical-grade materials are sourced or what tariff exposure those inputs carry, there’s more uncertainty in your cost structure than you may realize. Remington Medical works with OEMs who want a manufacturing relationship built on sourcing transparency and input cost stability.

Reach out to our team to discuss your program and what a more resilient raw material sourcing strategy could look like.

What OEMs Need to Know About Medical-Grade Material Sourcing With Tariffs

The Tariff Exposure Nobody’s Mapping

Three Materials, Three Exposure Stories

Medical-Grade Stainless Steel

Medical-Grade Resin and Specialty Polymers

Medical-Grade Silicone

Why Substitution Isn’t a Simple Fix

What This Means for How You Evaluate Your Manufacturing Relationship

The Raw Material Question Is a Manufacturing Partner Question

Get Clarity on Your Raw Material Exposure

Share This Post

More Like This

What a Customs Hold Is Really Costing Your Medical Device Supply Chain

How Offshore Sterilization and Lab Testing Can Delay Medical Device Launches

Where Tariff Risk Lives in Your Medical Device Supply Chain

Dual-Sourcing Doesn’t Work When Both Sources Are Offshore: Rethink

Why Choosing a U.S.-Based Contract Manufacturer Matters in a High-Tariff Trade Environment

How Contract Manufacturing for Medical Devices Accelerates Innovation

Scaling Production: How to Transition From Prototype to Manufacturing Medical Devices

Medical Device Compliance After Brexit: CE vs. UKCA

How to Find the Right Manufacturing Partner: Key Questions to Ask Your Contract Manufacturer

Get In Touch

Navigation

Recent Blogs